Nonvalvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism
Conditions
Interventions
Rivaroxaban anticoagulation therapy Observation group:None
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients (aged >=18 years) who were admitted to hospital due to diagnosis of deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation from January 2022 to October 2023 received rivaroxaban anticoagulation therapy during hospitalization or after discharge
Exclusion criteria
Exclusion criteria: 1.Patients with poor medication compliance, who fail to take their medication correctly as prescribed by the doctor or stop taking it at will; 2. Patients lost to follow-up; 3. Patients who alternate between domestic and original rivaroxaban.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of stroke/thromboembolism;Incidence of bleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| Coagulation indexes; | — |
Countries
China
Contacts
Public ContactWei Yuhui
The First Hospital of Lanzhou University
Outcome results
None listed